Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalantercept plus Axitinib in Advanced RCC (DART)
NCT01727336Phase 2Terminated
- Start
- Dec 2012
- Primary completion
- Jun 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dalantercept in clear cell renal cell carcinoma (ccRCC). Started Dec 2012; status: terminated.
02
Drugs
dalantercept
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01727336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01727336.